The DOI matches its Crossref record; the references it cites are not checked yet.
Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges
Open accessAbstract
Cancer immunotherapies have changed the landscape of cancer management and improved the standard treatment protocols used in multiple tumors. This has led to significant improvements in progression-free survival and overall survival rates. In this review article, we provide an insight into the major immunotherapeutic methods that are currently under investigation for colorectal cancer (CRC) and their clinical implementations. We emphasize therapies that are based on monoclonal antibodies (mAbs) and adoptive cell therapy, their mechanisms of action, their advantages, and their potential in combination therapy. We also highlight the clinical trials that have demonstrated both the therapeutic efficacy and the toxicities associated with each method. In addition, we summarize emerging targets that are now being evaluated as potential interventions for CRC. Finally, we discuss current challenges and future direction for the cancer immunotherapy field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“dual immunotherapies are being investigated, including two ICI combinations in patients with MSI-H/dMMR metastatic CRC to overcome primary resistance to ICI monotherapy [241].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [241]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 190 · Cited by 6
Metadata
- Authors
- Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F.
- Affiliations
- King Saud bin Abdulaziz University for Health Sciences (SA)
- Translational Research Institute and Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha 3050, Qatar
- Corresponding author
- Alammari, Farah
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-11-08
- Volume
- 23
- Issue
- 22
- Pages
- 13696
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9697544
- OpenAlex
- W4308506941
- Cited by
- 6
- References
- 190
- Citations by year
- 2026: 2 · 2025: 3 · 2023: 1
- FWCI
- 0.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- colorectal cancer, cancer immunotherapy, monoclonal antibodies, adoptive immunotherapy, combination therapy, immunotherapy toxicity, clinical trials
- MeSH terms
- Antineoplastic Agents, Immunological, Antibodies, Monoclonal, Humans, Immunotherapy, Colorectal Neoplasms, Immunotherapy, Adoptive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. https://app.cochat.ai/papers/10.3390/ijms232213696
- The paper
- Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022). Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms232213696
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.